Genzyme's Clolar needs more study in acute myeloid leukaemia, US panel says
This article was originally published in Scrip
Executive Summary
Genzyme should be required to conduct a randomised, controlled trial to demonstrate the efficacy and safety of Clolar (clofarabine) for elderly adults with acute myeloid leukaemia (AML), the US FDA's outside experts have said.